ArticleBMC pediatrics2025
Efficacy and safety of treprostinil in pediatric pulmonary hypertension following fontan surgery: a real-world analysis.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functionally Single-Ventricle Complications After Fontan Palliation-A Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThis study aimed to evaluate the efficacy and safety of treprostinil in managing pulmonary hypertension (PH) following Fontan surgery in children. The hypothesis was that early postoperative administration of treprostinil could reduce pulmonary arterial pressure and improve oxygenation, utilizing real-life data to better reflect clinical practice.
methodsA single-center, retrospective study was conducted at the Shanghai Children's Medical Center. The study included patients who underwent Fontan surgery between January 2015 and December 2023, comparing those treated with treprostinil (T Group) and those not treated (NT Group). Propensity-score matching was applied to adjust for baseline differences. Extracted demographic and clinical data included age, weight, height, type of cardiac defect, and surgical details. Postoperative variables included hemodynamic data, inotropic scores(IS), mean pulmonary arterial pressure(mPAP), pulmonary to systemic pressure ratio (Pp/Ps), PaO
resultsA total of 264 patients were identified, with 126 in the T Group and 138 in the NT Group. After matching, 154 patients were enrolled in (77 patients in each group). Mortality rates were similar (T: 0% vs NT: 1.3%, p=0.375). The T group showed significantly higher effective rates at both POD1 (90.9% vs.75.3%, p=0.010) and POD2 (93.5% vs. 79.2%, p=0.005). In patients receiving treprostinil ≥20 ng/kg/min, both mPAP and Pp/Ps showed significant reductions (p<0.001). Compared with baseline, the T group had significantly lower mPAP (P=0.045) and Pp/Ps (P=0.009), and a higher P/F ratio (P=0.02) on POD1. Significant main effects of treprostinil were observed for Pp/Ps (p<0.001), IS (p = 0.012), and P/F (p<0.001).T group had longer mechanical ventilation (p = 0.001) and ICU stay (p = 0.031). No major adverse events were observed.
conclusionTreprostinil treatment significantly reduced mPAP and Pp/Ps in the early postoperative period following Fontan surgery, with higher doses of treprostinil yielding more substantial hemodynamic improvements. But it did not significantly alter short-term clinical recovery, with no major adverse reactions observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.